An update on the role of nitrofurans in the management of urinary tract infections

Drugs

Volumn 61, Issue 3, 2001, Pages 353-364

  Guay, D R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFALOTIN; COTRIMOXAZOLE; NITROFURAL; NITROFURAN DERIVATIVE; NITROFURANTOIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CHEMICAL STRUCTURE; CLINICAL TRIAL; CYSTITIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; FLATULENCE; HEADACHE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; REVIEW; SKIN INFECTION; URINARY TRACT INFECTION; URINE CATHETER; UROGENITAL TRACT INFECTION;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 0035057158     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161030-00004     Document Type: Review

References (47)

1. Bacteriostatically acting nitro compounds of thiophenes and furans
2. Chemotherapeutic properties of prominent nitrofurans
3. Urinary tract agents: Nitrofurantoin and methenamine
4. Activity of a nitrofurazone matrix urinary catheter against catheter associated uropathogens
5. Nitrofurantoin: Mechanism of action and implications for resistance development in common uropathogens
6. Antimicrobial agents: Sulfonamides, trimethoprim-sulfamethoxazole, quinolones, agents for urinary tract infections
7. Studies on bacterial resistance to furacin
8. Mutations to nitrofurantoin and nitrofurazone in Escherichia coli K12
9. Nitrofurans, a group of synthetic antibiotics, with a new mode of action: Discrimination of specific messenger RNA classes
10. Inhibitory effects of some anti-inflammatory and other analgesics and nitrofurans on the induction of beta-galactosidase synthesis in Klebsiella aerogenes
11. Nitrofurans
12. Reappraisal of the risk/benefit of nitrofurantoin: Review of toxicity and efficacy
13. Effect of blood and serum on in vitro antibacterial activity of nitrofurazone
14. Drug therapy reviews: Nitrofurantoin
15. Non-absorption of nitrofurazone from the urethra in men
16. Non-absorption of furazolidone from the vagina in women
17. Effectiveness of a nitrofuran in the treatment of infected wounds. I. Preliminary report
18. Clinical observations of furacin soluble dressing in treatment of surface infections
19. Re-evaluation of furacin as a local agent in the treatment of surface infections
20. Susceptibility of Enterobacteriaceae to nitrofurantoin correlated with eradication of bacteriuria
21. Species incidence and trends of susceptibility to antibiotics in the United States and other countries: MIC and MBC
22. Antibiotic resistance in the genitourinary system
23. Antibiotic resistance in community-acquired urinary tract infections
24. Nosocomial urinary tract infections
25. Catheter-associated urinary tract infections
26. Clinicians running out of ammo as pathogens build defenses
27. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women
28. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women
29. Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years' experience
30. Uncomplicated E. coli urinary tract infection in college women: A retrospective study of E. coli sensitivities to commonly prescribed antibiotics
31. Recurrent urinary tract infection: Prevention by prophylactic antibiotics after sexual intercourse
32. Vaginal antibiotic for surgery. Bacterial evaluation of the effect of Furacin vaginal suppositories in relation to morbidity following major vaginal surgery
33. Clinical experience with furacin in external ocular infections
34. The use of Furacin topical cream in the treatment of fire ant bites
35. The role of topical medications in the management of stasis ulcers
36. Nitrofurazone in the treatment of bacterial ear infections: Re-evaluation after twenty years
37. Is nitrofurazone a primary irritant or a potent sensitizer: A review of the literature, 1945-1965, and cases reported to medical director
38. Catheter-associated bacteriuria. An experimental study
39. A prospective study of pathogenesis of catheter-associated urinary tract infections
40. Catheter-associated urinary tract infections: Epidemiology, pathogenesis, and prevention
41. Activities of a nitrofurazone-containing urinary catheter and a silver hydrogel catheter against multidrug-resistant bacteria characteristic of catheter-associated urinary tract infection
42. How long should catheter-acquired urinary tract infection in women be treated? A randomized, controlled study
43. Nitrofurantoin